February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and survivorship lung health.
Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid ...
(PTx) announced findings from a post hoc analysis of the eNRGy trial (NCT02912949) evaluating treatment beyond progression with zenocutuzumab in patients with advanced neuregulin 1 fusion-positive ...
Spatial maps of lung precancer and cancer cells at different points in development advance understanding of the earliest stages of lung cancer Findings highlight inflammation as a driver of lung tumor ...
CHICAGO -- SGLT2 inhibitor use was linked to reduced progression of in-situ pulmonary adenocarcinoma, an observational study showed. Nodule growth over the median 28 months of follow-up was 62% less ...
In this video, Lukas Delasos, DO, an associate staff member of the Lung Cancer Medical Oncology Program at the Cleveland Clinic Taussig Cancer Institute, discusses results from the HARMONi trial ...
Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI)-powered Software as Medical Devices (SaMDs) for early cancer ...
As a nonsmoker lung cancer hasn't been a concern of mine, but I recently heard it can affect people who have never smoked. If ...
Add Yahoo as a preferred source to see more of our stories on Google. MIDLAND, Texas (KMID/KPEJ)- The Texas Medical Association reported fewer cases of lung cancer across Texas in 2025. “What we’ve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results